Gynesonics Announces Publication of Clinical Study Analysis Demonstrating Effectiveness of the Sonata System in Treating Submucous and Large Symptomatic Uterine Fibroids
The article is an analysis of a subgroup of patients with submucous or large fibroids from two previously published multicenter prospective clinical trials (FAST-EU and SONATA) of transcervical fibroid ablation (TFA) with the Sonata System.
The outcomes reported in the paper build upon the previously published 12-month and 24-month outcomes, demonstrating the sustained durability of patient benefits through three years which include a significant reduction in fibroid related symptoms.
Sonata demonstrates significant advantages in reducing procedure time, length of stay and procedure-related costs compared to myomectomy.
Gynesonics Reports Sonata System Assists Facilities Impacted by the COVID-19 Pandemic in Restarting Elective Gynecologic Procedures
Sonata integrates the first and only intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device to treat symptomatic fibroids in a transcervical, incision-free, uterus-preserving manner.
The new advances in Sonata® System 2.1 include a new integrated treatment device design that enables all procedure steps to be performed on the sterile field and in the palm of the physician’s hand.